Biomarkers associated with high-density lipoproteins in atherosclerotic kidney disease

Area of Science:

• Cardiovascular Science
• Lipid Metabolism
• Protein Chemistry

Background:

• High-density lipoproteins (HDL) are crucial for cholesterol transport and cardiovascular health.
• Apolipoprotein A-I (apoA-I) is the primary protein in HDL, facilitating cholesterol removal and possessing antioxidant properties.
• Diabetes and renal disease are linked to impaired HDL function and increased cardiovascular risk.

Purpose of the Study:

• To review the impact of non-enzymatic glycation of apoA-I on HDL structure and function.
• To investigate how glycated apoA-I affects lecithin:cholesterol acyltransferase (LCAT) activity.
• To examine the consequences of apoA-I glycation on cholesterol efflux and HDL's anti-inflammatory/antioxidant properties.

Main Methods:

• Review of existing literature on HDL metabolism, apoA-I glycation, and cardiovascular disease.
• Analysis of studies investigating the effects of non-enzymatic glycation on LCAT activity.
• Examination of research on cholesterol efflux from macrophages mediated by HDL.

Main Results:

• Non-enzymatic glycation of apoA-I alters HDL particle formation and function.
• Glycation of apoA-I inhibits the LCAT reaction, hindering the conversion of discoidal to spherical HDL.
• Impaired cholesterol efflux and reduced anti-inflammatory/antioxidant properties of HDL are associated with glycated apoA-I.

Conclusions:

• Non-enzymatic glycation of apoA-I is a significant factor in the compromised cardioprotective functions of HDL observed in diabetes and renal disease.
• Understanding these mechanisms is vital for developing strategies to mitigate cardiovascular risk in these patient populations.
• Further research is needed to fully elucidate the complex interplay between glycation, HDL function, and cardiovascular outcomes.